Form 4: Robert Nelsen, Director and 10% Owner of Sana Biotechnology, Acquires 54,278 Stock Options

Robert Nelsen, a director and 10% owner of Sana Biotechnology, acquired 54,278 stock options on June 6, 2024, exercisable at $7.36.

Summary

• On June 6, 2024, Robert Nelsen, a director and 10% owner of Sana Biotechnology, Inc. (Sana), acquired 54,278 stock options.
• The exercise price of these options is $7.36.
• The options vest and become exercisable as to 100% of the underlying shares on the earlier of June 6, 2025, or immediately prior to the 2025 annual meeting of stockholders, contingent upon continuous service to Sana through that date.
• Following the transaction, Nelsen directly owns 54,278 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction by a company insider, indicating continued investment but not necessarily a major shift in outlook.

Positives

• Acquisition of stock options by a director and significant shareholder signals confidence in the company's future prospects.

Future Outlook

The vesting of the options is contingent upon continuous service to Sana Biotechnology through June 6, 2025, or immediately prior to the 2025 annual meeting of stockholders.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's continued investment in the company.

Stakeholder Impact

• The acquisition of stock options by a director may have a slightly positive impact on shareholder confidence.

Key Dates